行政任职（Administrative positions）：
5848vip威尼斯电子游戏附属东方医院肝胆胰外科副主任/执行主任
Deputy Director/Executive Director of Hepatobiliary and Pancreatic Surgery, East Hospital of Tongji University
5848vip威尼斯电子游戏肝胆胰外科研究副所长
Deputy Director, Institute of Hepatobiliary and Pancreatic Surgery, Tongji University School of Medicine
学术任职（Academic position）：
中国抗癌协会胆道肿瘤专业委员会 委员
Member of Biliary tract Tumor Professional Committee of Chinese Anti-Cancer Association
中国抗癌协会腹膜肿瘤专业委员会 委员
Member of the Professional Committee of peritoneal Tumor, Chinese Anti-Cancer Association
中国医药生物技术协会精准医疗分会 委员
Member of Precision Medicine Branch of China Medical Biotechnology Association
中国医药教育协会中医药教育促进工作委员会 常务委员
Standing member of Chinese Medicine Education Promotion Working Committee, China Medical Education Association
上海市抗癌协会胆道肿瘤专业委员会 委员
Member of Biliary tract Tumor Professional Committee of Shanghai Anticancer Association
上海市浦东新区卫生系统学科带头人
Academic leader of Shanghai Pudong Health Bureau
上海市浦东新区医学会肝胆外科专业委员会 副主任委员
Deputy Chairman of the hepatobiliary Surgery Committee of Shanghai Pudong Medical Association
上海市浦东新区医学会肝病专业委员会 委员
Member of Liver disease Professional Committee of Shanghai Pudong District Medical Association
发表论著（Publications）：
1.Jinghan Wang; Hongming Yu; Wei Dong; Cheng Zhang; Mingtai Hu; Wencong Ma; Xiaoqing Jiang; Hengyu Li; Pinghua Yang; Daimin Xiang ; N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways. Gastroenterology, 2023, S0016-5085(23): 00114-2. (IF 33.8)
2.Jinghan Wang; Meng Ren; Jundan Yu; Mingtai Hu; Xiaojing Wang; Wencong Ma; Xiaoqing Jiang; Jie Cui. Single-cell RNA sequencing highlights the functional role of humanendogenous retroviruses in gallbladder cancer. eBioMedicine, 2022, 85: 104319.(IF 11.2)
3.Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, Wu Y, Han T, Xiang D. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022 Jan 6;15(1):2. (IF 23)
4.Shen S, Wang R, Qiu H, Li C, Wang J, Xue J, Tang Q. Development of an Autophagy-Based and Stemness-Correlated Prognostic Model for Hepatocellular Carcinoma Using Bulk and Single-Cell RNA-Sequencing. Front Cell Dev Biol. 2021 Nov 8;9:743910. （IF 6.0）
5.Qian F, Wang J, Wang Y, Gao Q, Yan W, Lin Y, Shen L, Xie Y, Jiang X, Shen B. MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation.Clin Transl Med. 2021 Feb;11(2):e307.（IF 8.5）
6.Wang J, Xu C, Cheng Q, Zhao J, Wu S, Li W, Ma W, Liu C, Jiang X. RNA Sequencing Revealed Signals of Evolution From Gallbladder Stone to Gallbladder Carcinoma. Front Oncol. 2020 May 29;10:823. （IF 6.2）
7.Wencong M, Jinghan W, Yong Y, Jianyang A, Bin L, Qingbao C, Chen L, Xiaoqing J. FOXK1 Promotes Proliferation and Metastasis of Gallbladder Cancer by Activating AKT/mTOR Signaling Pathway. Front Oncol. 2020 Apr 17;10:545. （IF 6.2）
8.Zhang K, Wang J, Wang J, Luh F, Liu X, Yang L, Liu YR, Su L, Yang YS, Chu P, Yen Y. LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.Am J Cancer Res. 2019 Aug 1;9(8):1650-1663. （IF 7.12）
9.Ma W, Li W, Wang J, Wu R, Liu C, Feng F, Jiang X. The Clinical Role of Preoperative Serum CA19-9 and Carcinoembryonic Antigen (CEA) Levels in Evaluating the Resectability of Advanced Gallbladder Cancer. Med Sci Monit. 2020 Sep 20;26:（IF 1.9）
10. Hu MT, Wang JH, Yu Y, Liu C, Li B, Cheng QB, Jiang XQ. Tumor suppressor LKB1 inhibits the progression of gallbladder carcinoma and predicts the prognosis of patients with this malignancy. Int J Oncol. 2018 Sep;53(3):1215-1226. （IF 5.88）
11. Li J, Yu Y, Wang J, Yan Z, Liu H, Wang Y, Ding M, Cui L, Wu M, Jiang X, Qian Q. Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells. Cancer Lett. 2015 May 1;360(2):177-86.（IF 9.75）
12. Wang JH, Li LF, Yu Y, Li B, Jin HJ, Shen DH, Li J, Jiang XQ, Qian QJ.Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer. Oncol Rep. 2012 Mar;27(3):775-82. doi:
13.Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma. Oncotarget. 2015 Aug 7;6(22):18905-20. doi:
14.Yu Y, Wang J, Xia N, Li B, Jiang X. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells. Oncol Rep. 2015 Apr;33(4):1683-90. doi: 10.3892/or.2015.3755.
15.Wang J, Li L, Zhang K, Yu Y, Li B, Li J, Yan Z, Hu Z, Yen Y, Wu M, Jiang X, Qian Q. Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma.PLoS One. 2013;8(1):e54377. doi: 10.1371/journal.pone.0054377. Epub 2013 Jan 30.
16.Wang J, Yu Y, Yan Z, Hu Z, Li L, Li J, Jiang X, Qian Q. Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo. Oncol Rep. 2013 Aug;30(2):833-41.
主持科研项目（Research grant）：
上海市浦东新区卫生系统学科带头人培养计划，HLF调控胆囊癌进展和免疫耐受的机制及临床应用研究，PWRd2022-05。
Funded by Academic Leaders Training Program of Pudong Health Bureau of Shanghai。Study on the mechanism and clinical application of HLF in regulating the progression and immune tolerance of gallbladder cancer。PWRd2022-05.
浦东新区科技发展基金事业单位民生科研专项，SCD1调控胆囊癌进展和免疫耐受的机制及临床应用研究，PKJ2022-Y18。
Pudong New Area Science and Technology Development Fund Public Institutions Livelihood Research Project, SCD1 regulation of gallbladder cancer progression and immune tolerance mechanism and clinical application research, PKJ2022-Y18
上海市东方医院人才引进科研启动经费，SCD1调控胆囊癌进展和免疫耐受的机制及临床应用研究。
Shanghai East Hospital introduced talents and research start-up funds. Study of the mechanism and clinical application of SCD1 in regulating gallbladder cancer progression and immune tolerance.
